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Abstract
Peptic ulcer bleeding remains a common cause of hospital admission, morbidity and mortality. Data
published since 2006 illustrate that assessment, endoscopic and pharmacological management, and
follow-up strategies can be refined to improve the overall prognosis of peptic ulcer bleeding.
Introduction and context
Acute upper gastrointestinal bleeding remains an impor-
tant medical emergency. A recent large nationwide audit
in the UK (6,750 cases) showed that overall rates of
admission to hospital were 103 out of 100,000 adults,
with an overall mortality of 10% in new admissions and
26% in those who have a gastrointestinal haemorrhage
whilst an inpatient. Peptic ulcer bleeding (PUB) remains
the single most common cause of upper gastrointestinal
haemorrhage (36% of cases) and the UK audit showed a
mortality of 3.8% in patients under 60 years old rising to
10% in patients over 80 years old [1]. These results are
rather worse than those reported in trials in specialist
centres and probably reflect the increasing age and co-
morbidity of patients in the ‘real world’, as well as the
relatively slow spread of optimal practice (for instance,
only 6% of patients had dual endoscopic therapy [1]).
Recent studies have further refined our management
strategies for PUB and these can be viewed in terms of
risk scoring and stratification, resuscitation, endoscopic
therapy, pharmacotherapy and prevention.
Recent advances
Risk stratification and scoring
The Rockall score is widely used to compare outcomes
and is very useful as an audit tool, having been validated
in several populations [2]. It performs less well as a guide
to management, especially in predicting very low-risk
bleeders, who can safely be discharged without hospital
admission. The Glasgow-Blatchford score (GBS) was
initially shown to be superior in defining this low risk
group and a recent validation study in 676 separate
patients confirmed that a score of 0 [pulse <100, systolic
blood pressure >110 mmHg, urea <6.5 mmol/l, haemo-
globin >13.0 g/dl (men) or 12.0 g/dl (women), and an
absence of syncope, melaena, heart failure or liver
disease] was associated with a zero rate of death,
transfusion or endoscopic intervention [3]. A Canadian
study utilised a modified GBS (omitting urea and
syncope) and although effective, it did perform less
well than the full score (5% re-bleeding rate in the 0
scoring group) [4]. Thus, early discharge strategies based
on the full GBS scoring system should be implemented
to increase efficient use of resources.
Resuscitation
Whilst prompt and appropriate fluid resuscitation is
essential to the effective management of PUB, there are
remarkably few data on which to base management and
transfusion strategies and these remain essentially
clinical decisions. An increasing number of patients
with PUB have been treated with vitamin K antagonists
such as warfarin, and the availability of prothrombin
complex concentrate (which contains factors II, VII, IX
and X) is a real advance in the reversal of anticoagulation
in such patients [5]. Although never examined specifi-
cally in PUB, the rapid and effective reversal of antic-
oagulation achieved with this agent implies it should be
central to the resuscitation of actively bleeding patients
on warfarin.
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A variety of endoscopic methods are available to treat
PUB, with new devices coming to the market regularly.
Guidelines recommend the use of injection therapy plus
either thermal coagulation or endoclips [6]. Systematic
reviews have confirmed that combined therapy is more
effective than adrenaline injection alone, but it has not
been shown that combined therapy is better than clips or
thermal coagulation alone and these two modalities
alone were found to be equivalent [7-9].
Two recent studies have examined the efficacy of the
newly developed triclip: in both a simulator model [10]
and clinical practice, results were worse than with
standard clips, mainly because of difficulty in placing
this clip accurately [11]. A systematic review confirmed
that endoclips are less effective for PUB lesions on the
posterior duodenal wall, posterior gastric wall, and lesser
curve because of difficulty placing the clips [8].
Adrenaline injection is probably the easiest and most
widely available endoscopic technique and may be used
alone when other methods are unavailable. The optimal
volume of adrenaline for combination therapies is
unclear, but recent studies have clarified the dose when
used alone. Liou et al. [12] compared 20, 30 and 40 ml of
1:10,000 adrenaline (epinephrine). Initial haemostasis
was equivalent but the smallest volume was associated
with significantly more re-bleeding and the 40 ml dose
was associated with an unacceptable perforation rate
(6.6%), suggesting that when used alone, 30 ml would be
the optimal dose. Injection regimes were further refined
when 40 ml 1:10,000 adrenaline alone was compared
with 40 ml saline alone or enough adrenaline to produce
initial haemostasis followed by saline to a total volume of
40 ml. Initial haemostasis was higher in both the
adrenaline groups (both 98.6%) than the saline alone
group(88.9%)butre-bleedingratesweresimilar(approxi-
mately 5%). Perforation occurred in 2.8% of the adrena-
line alone group [13]. These volumes are rather higher
than most Western endoscopists generally use, but these
datashouldencourage are-examinationofthesepractices.
Although multimodality endoscopic therapies are prefer-
able, when other methods are unavailable, adrenaline
followed by saline would seem to be appropriate.
Pharmacotherapy
Potent acid suppressive therapy to stabilise the fibrin clot
in the acute situation has always been an attractive idea
and proton pump inhibitors (PPIs) are widely used for
this. However, data on the most effective way to use these
agents are conflicting. High dose intravenous omepra-
zole (80 mg bolus followed by 8 mg/h for 72 hours) after
endoscopic therapy has been widely used following the
landmark study of Lau et al. [14]. However the effects of
pharmacodymanics, physiology and Helicobacter pylori
infection in the Asian population in that study mean that
it may not be generalisable to other groups. A Cochrane
systematic review (including the data from Lau et al.)
confirmed that PPIs reduce re-bleeding and surgery in
PUB but did not show the superiority of any dose or
route of administration [15]. The beneficial effects were
significantly more pronounced in the studies in Asian
populations. One important point is that all the studies
in the systematic review used oral or parenteral PPIs at
higher than standard ulcer healing doses [15].
Subsequent recent studies examining the effects after
endoscopic therapy have only added to the confusion.
A retrospective Canadian study of 162 patients [16]
showed that oral omeprazole (at least 40 mg) was as
effective as omeprazole infusion following endoscopic
haemostasis. A North American trial comparing parent-
eral high-dose pantoprazole with intravenous ranitidine
was stopped early because of slow recruitment [17]; no
significant differences were seen, although re-bleeding
was numerically lower with pantoprazole (6.9 versus
14.3%). A similar randomized study predominantly in
Europeans showed that intravenous pantoprazole was
not superior to intravenous ranitidine, although re-
bleeding rates in that study were very low (2.9-3.2%)
[18]. A further trial in India (203 patients) showed that
intravenous pantoprazole was superior to placebo,
reducing re-bleeding (7.8 versus 19.8%) and transfu-
sions [19]. A Greek study of 164 patients showed that
intravenous pantoprazole was more effective than
somatostatin in preventing re-bleeding (5 versus 17%)
despite equivalent actions on gastric pH [20]. Thus, it
seems that PPI therapy is mandatory for PUB and whilst
high dose infusions are very effective in Asian popula-
tions, the optimal regimens for Caucasians still need to
be established. A recently published large study [21]
showed that intravenous esomeprazole bolus (80 mg)
followed by infusion for 72 hours (8 mg/h) did
significantly reduce re-bleeding (5.9 versus 10.3%) and
endoscopic retreatment (6.4 versus 11.6%) compared to
placebo in a predominantly Caucasian population (767
patients) and this may yet become the treatment of
choice following endoscopic therapy.
The effect of potent acid suppression before endoscopy
has also been investigated. Lau et al. [22] showed that
parenteral omeprazole reduced endoscopic stigmata and
need for intervention, but a further Cochrane analysis
confirmed only that pre-endoscopy PPI reduced high-
risk endoscopic stigmata without affecting the clinically
important outcomes (mortality, re-bleeding or surgery)
[23].
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It is accepted that H. pylori, cyclo-oxygenase inhibitors
and antiplatelet drugs are the main remedial causes of
PUB. Gisbert et al. [24] confirmed the importance of
H. pylori. Following successful eradication (which may
require sequential treatment strategies) the rate of re-
bleeding was only 0.22% per year and patients did not
require long-term acid suppressive therapy. Against this,
a systematic review of H. pylori testing in PUB [25]
showed that all tests except urea-breath testing (sensitiv-
ity 93%), especially biopsy-based ones (sensitivities
45-70%), had decreased sensitivity in PUB. Faecal
antigen testing performed relatively well (sensitivity
87%). These studies confirm that strategies to identify,
treat and follow up H. pylori are essential in the
management of PUB.
Although the initial promise of the cyclo-oxygenase-2
(COX-2) selective agents has been tempered by worries
about their cardiovascular toxicity and the realisation
that they are not without gastrointestinal effects, these
agents do offer some advantages in selected patients with
regards to PUB. In the colonic adenoma prevention trial,
rofecoxib (now withdrawn, but a very selective COX-2
inhibitor) was associated with PUB rates significantly
greater than placebo (0.23 versus 0.06 per 100 patients-
years), showing these are not a panacea for peptic ulcers
[26]. However, a large population-based case-control
study confirmed that COX-2 selective agents were
associated with lower rates of PUB than traditional
nonsteroidal anti-inflammatory drugs (NSAIDs) and
residual risk was significantly reduced by co-prescription
of a PPI [27].
Previously, celecoxib was shown to be equivalent to
diclofenac plus PPI following PUB (re-bleeding rates
4.9 versus 6.4%) [28] and an important study, again
from Hong Kong, showed that celecoxib plus esome-
prazole was better than celecoxib alone following PUB
(re-bleeding rates 0 versus 8.9%) [29]. There still may be
differences between the various cyclo-oxygenase inhibi-
tors but this regimen does offer a way forward for those
requiring continued anti-inflammatory therapy after
PUB.
Clopidogrel is associated with a significantly increased
rate of PUB. Following an aspirin-induced PUB,
clopidogrel alone was worse than aspirin plus PPI
(re-bleeding rates after 52 weeks, 13.6 versus 0%) [30].
The addition of clopidogrel to aspirin does increase the
absolute risk of PUB in those without a previous history
of the condition, by about 1% per year (0.3% increased
to 1.4%) [31]. In view of this relatively low excess risk
and the recent data suggesting that PPIs can significantly
reduce the cardioprotective effects of clopidogrel [32],
and the lack of proven efficacy for H2-receptor anta-
gonists in this situation [33], primary prophylaxis with a
PPI is probably not indicated.
A difficult situation arises in those patients with PUB and
a recently inserted coronary stent or unstable coronary
syndrome. In these patients, discontinuation of dual
antiplatelet agents is associated with a significant risk of
adverse cardiovascular events (29% at 1 month [34]). In
a small (88 patients) but important study, Ng et al. [35]
showed that when antiplatelets were reintroduced within
1 week of PUB with PPI cover, the re-bleeding rate was
0% at 3 months. These results require duplication but
suggest that antiplatelets can be reintroduced early after
cessation of PUB.
Implications for clinical practice
The GBS score provides a secure evidence base to limit
hospital admissions and investigations in low-risk
patients. Combined endoscopic therapies are superior
to adrenaline alone. When endoclips or thermocoagula-
tion are unavailable, initial adrenaline followed by saline
to a total volume of 40 ml seems the optimal injection
regimen. Following cessation of bleeding, continued
management should include searching for and eradicat-
ing H. pylori and strategies to minimise further drug-
induced PUB. Aspirin combined with a PPI is preferable
to clopidogrel following aspirin-induced PUB, and
should anti-inflammatory drugs need to be reintroduced
in this high-risk group, celecoxib plus esomeprazole
seems to be the regimen of choice, bearing in mind
cardiovascular risk factors. In the highest cardiovascular
risk patients, early reintroduction of antiplatelets seems
relatively safe, although further confirmatory studies are
required as are further data on the interactions between
antiplatelets and PPIs.
PPIs are mandatory after endoscopy in PUB, but the
optimal regimen and drug do require further definition,
especially in non-Asian patients. The best evidence is for
high dose intravenous esomeprazole in this group of
patients. High-dose PPI therapy before endoscopy does
not affect major clinical outcomes, and should probably
be reserved for patients in whom expedient endoscopy is
not possible.
Abbreviations
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